Dr. Keith Stockerl-Goldstein

About Keith Stockerl-Goldstein

Education:

• Obtained a BA in Biology from Washington University, Saint Louis, Missouri, 1986.
• Earned an MD from the University of California Los Angeles (UCLA) School of Medicine, 1991.
• Completed Residency in Internal Medicine at Stanford University Hospital, 1993.
• Undertook Fellowships in Bone Marrow Transplantation (1995) and Medical Oncology (1996) at Stanford University School of Medicine.

Experience:

• Former Clinical Director of Adult Bone Marrow Transplantation Unit at Stanford University School of Medicine.
• Currently serves as Program Director for Hematology-Medical Oncology & Hematology Focused Fellowship Training Program at Washington University School of Medicine.
• Holds the position of Associate Program Director for Bone Marrow Transplantation at the same institution.

Area of expertise

Affiliated Hospitals

Washington University School Of Medicine

Siteman Cancer Center-South County

Clinical Trials Keith Stockerl-Goldstein is currently running

Motixafortide + G-CSF

for Multiple Myeloma

This study includes extended CD34+ profiling on the apheresis product of multiple myeloma patients undergoing standard-of-care quad-induction followed by motixafortide + G-CSF mobilization, and in addition, assesses the pharmacodynamics (PD) of motixafortide following "standard" (\~12 hours) vs "early" (\~16 hours) dosing. The investigators hypothesize that quad-induction may alter the stem cell subsets within the mobilized graft. The investigators further hypothesize that standard and early dosing strategies will result in comparable mobilization and stem cell collection rates.

Recruiting1 award Phase 16 criteria

CIML NK Cell Therapy

for Acute Myeloid Leukemia

This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort). A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (\>60% any grades or \>30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).

Recruiting1 award Phase 2

More about Keith Stockerl-Goldstein

Other Doctors you might be interested in

Frequently asked questions